EMA Recommends Granting a Marketing Authorisation for Quizartinib
It is intended for the treatment of adult patients with newly diagnosed FLT3-ITD positive AML
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
It is intended for the treatment of adult patients with newly diagnosed FLT3-ITD positive AML
Findings from the HERTHENA-Lung01 study
Findings from the CC-92480-MM-001 study
Primary results from DESTINY-Lung02 study
Evidence for efficacy is based on the results from the MagnetisMM-3 study
It is intended in combination with trametinib for the treatment of low- and high-grade gliomas
Findings from the NAPOLI 3 study
Findings from the phase II study
Findings from a meta-analysis
Findings from a phase II study
Findings from the TROPiCS-02 study
Evidence for efficacy is based on results from the MonumenTAL-1 study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.